Advice

following an abbreviated submission:

valganciclovir powder for 50mg/ml oral solution (Valcyte) is accepted for restricted use in NHS Scotland for the prevention of CMV disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor.

Valganciclovir should only be initiated by physicians experienced in the care of post transplant patients. In patients for whom valganciclovir is an appropriate choice of therapy this is the only licensed formulation for those undergoing haemodialysis (creatinine clearance <10ml/minute).

Otherwise its use should be restricted to patients unable to use the less costly solid oral dosage form.

Download detailed advice44KB (PDF)

Download

Medicine details

Medicine name:
valganciclovir (Valcyte)
SMC ID:
587/09
Indication:
AIDS & Solid Organ Transplantation
Pharmaceutical company
Roche
BNF chapter
Infections
Submission type
Abbreviated
Status
Restricted
Date advice published:
07 December 2009